Immunovant (IMVT) Stock Forecast, Price Target & Predictions
IMVT Stock Forecast
Immunovant stock forecast is as follows: an average price target of $42.83 (represents a 61.38% upside from IMVT’s last price of $26.54) and a rating consensus of 'Buy', based on 22 wall street analysts offering a 1-year stock forecast.
IMVT Price Target
The average price target for Immunovant (IMVT) is $42.83 based on 1-year price targets from 22 Wall Street analysts in the past 3 months, with a price target range of $57.00 to $5.00. This represents a potential 61.38% upside from IMVT's last price of $26.54.
IMVT Analyst Ratings
According to 22 Wall Street analysts, Immunovant's rating consensus is 'Buy'. The analyst rating breakdown for IMVT stock is 0 'Strong Buy' (0.00%), 16 'Buy' (72.73%), 4 'Hold' (18.18%), 2 'Sell' (9.09%), and 0 'Strong Sell' (0.00%).
Immunovant Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 10, 2024 | Douglas Tsao | H.C. Wainwright | $51.00 | $30.20 | 68.87% | 92.16% |
| Jun 03, 2024 | Leland Gershell | Oppenheimer | $46.00 | $25.39 | 81.17% | 73.32% |
| May 30, 2024 | Yatin Suneja | Guggenheim | $48.00 | $26.41 | 81.75% | 80.86% |
| May 30, 2024 | Yasmeen Rahimi | Piper Sandler | $57.00 | $27.83 | 104.81% | 114.77% |
| Mar 13, 2024 | Corinne Johnson | Goldman Sachs | $50.00 | $31.82 | 57.13% | 88.39% |
| Sep 26, 2022 | Colin Bristow | UBS | $5.00 | $4.88 | 2.46% | -81.16% |
The latest Immunovant stock forecast, released on Sep 10, 2024 by Douglas Tsao from H.C. Wainwright, set a price target of $51.00, which represents a 68.87% increase from the stock price at the time of the forecast ($30.20), and a 92.16% increase from IMVT last price ($26.54).
Immunovant Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 5 |
| Avg Price Target | - | $51.00 | $50.40 |
| Last Closing Price | $26.54 | $26.54 | $26.54 |
| Upside/Downside | -100.00% | 92.16% | 89.90% |
In the current month, the average price target of Immunovant stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Immunovant's last price of $26.54. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 09, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Sep 25, 2024 | Goldman Sachs | Buy | Buy | Hold |
| Sep 12, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Sep 10, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Sep 09, 2024 | Citigroup | Buy | Buy | Hold |
| Jun 03, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| May 31, 2024 | Wells Fargo | Overweight | Overweight | Hold |
| May 30, 2024 | Guggenheim | Buy | Buy | Hold |
| May 30, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| May 29, 2024 | Goldman Sachs | Neutral | Neutral | Hold |
Immunovant's last stock rating was published by Oppenheimer on Oct 09, 2024. The company gave IMVT a "Outperform" rating, the same as its previous rate.
Immunovant Financial Forecast
Immunovant Revenue Forecast
| Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - |
Immunovant's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. IMVT's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Immunovant EBITDA Forecast
| Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - |
undefined analysts predict IMVT's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Immunovant's previous annual EBITDA (undefined) of $NaN.
Immunovant Net Income Forecast
| Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - | - |
| Avg Forecast | $-123.03M | $-118.84M | $-118.64M | $-114.66M | $-105.22M | $-104.67M | $-86.24M | $-76.54M |
| High Forecast | $-123.03M | $-118.84M | $-118.64M | $-114.66M | $-80.72M | $-82.56M | $-86.24M | $-76.54M |
| Low Forecast | $-123.03M | $-118.84M | $-118.64M | $-114.66M | $-118.19M | $-117.94M | $-86.24M | $-76.54M |
| Surprise % | - | - | - | - | - | - | - | - |
Immunovant's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. IMVT's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Immunovant SG&A Forecast
| Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - |
Immunovant's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to IMVT last annual SG&A of $NaN (undefined).
Immunovant EPS Forecast
| Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - | - |
| Avg Forecast | $-0.84 | $-0.81 | $-0.81 | $-0.78 | $-0.72 | $-0.71 | $-0.59 | $-0.52 |
| High Forecast | $-0.84 | $-0.81 | $-0.81 | $-0.78 | $-0.55 | $-0.56 | $-0.59 | $-0.52 |
| Low Forecast | $-0.84 | $-0.81 | $-0.81 | $-0.78 | $-0.81 | $-0.81 | $-0.59 | $-0.52 |
| Surprise % | - | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Immunovant's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to IMVT previous annual EPS of $NaN (undefined).
Immunovant Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PLRX | Pliant Therapeutics | $12.85 | $39.71 | 209.03% | Buy |
| ARQT | Arcutis Biotherapeutics | $10.24 | $31.00 | 202.73% | Buy |
| DAWN | Day One Biopharmaceuticals | $13.34 | $38.80 | 190.85% | Buy |
| STOK | Stoke Therapeutics | $11.27 | $30.60 | 171.52% | Buy |
| APLS | Apellis Pharmaceuticals | $27.75 | $74.50 | 168.47% | Buy |
| ETNB | 89bio | $8.38 | $22.00 | 162.53% | Buy |
| ABUS | Arbutus Biopharma | $3.46 | $8.50 | 145.66% | Buy |
| LEGN | Legend Biotech | $39.75 | $82.69 | 108.03% | Buy |
| IMVT | Immunovant | $26.54 | $42.83 | 61.38% | Buy |
| AKRO | Akero Therapeutics | $31.20 | $46.00 | 47.44% | Buy |
| AMLX | Amylyx Pharmaceuticals | $5.19 | $6.67 | 28.52% | Buy |
| PTGX | Protagonist Therapeutics | $41.65 | $50.00 | 20.05% | Buy |
| BPMC | Blueprint Medicines | $96.62 | $109.71 | 13.55% | Buy |
| MDGL | Madrigal Pharmaceuticals | $329.24 | $315.75 | -4.10% | Buy |
| ACLX | Arcellx | $87.22 | $83.00 | -4.84% | Buy |
| KRTX | Karuna Therapeutics | $329.83 | $257.50 | -21.93% | Buy |